Position in VTGN
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$28,409
-$83,366 QoQ
Shares Held
49,842
+58.3% QoQ
Ownership
0.121%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VTGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GSA CAPITAL PARTNERS LLP holds $100,711,343 across 163 Biotechnology names. VTGN ranks #156 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,831 | $2,959,983 | |
| 2 | ARDX |
Ardelyx, Inc.
|
473,061 | $2,833,635 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
178,301 | $2,285,818 | |
| 4 | NUVB |
Nuvation Bio Inc.
|
495,792 | $2,126,947 | |
| 5 | RXRX |
Recursion Pharmaceuticals, Inc.
|
669,568 | $2,055,573 | |
| 6 | WVE |
Wave Life Sciences Ltd.
|
282,719 | $2,049,712 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
90,960 | $1,979,289 | |
| 8 | IOVA |
Iovance Biotherapeutics, Inc.
|
557,085 | $1,955,368 |
All Filings in VTGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $28,409 | 49,842 | Shares | Sole | 2026-05-08 | |
| 2025-09-30 | $111,775 | 31,486 | Shares | Sole | 2025-11-07 | |
| 2023-09-30 | $245,137 | 46,782 | Shares | Sole | 2023-11-15 | |
| 2023-06-30 | $371,785 | 198,816 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||